PolyPeptide Group Management
Management criteria checks 2/4
PolyPeptide Group's CEO is Juan Gonzalez, appointed in Apr 2023, has a tenure of 3.08 years. total yearly compensation is €3.08M, comprised of 28.1% salary and 71.9% bonuses, including company stock and options. directly owns 0.69% of the company’s shares, worth CHF9.28M. The average tenure of the management team and the board of directors is 3.5 years and 5.3 years respectively.
Key information
Juan Gonzalez
Chief executive officer
€3.1m
Total compensation
| CEO salary percentage | 28.06% |
| CEO tenure | 3.1yrs |
| CEO ownership | 0.7% |
| Management average tenure | 3.5yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
Metabolics Shift And New Capacity Will Support Long Term Peptide CDMO Opportunity
Catalysts About PolyPeptide Group PolyPeptide Group is a contract development and manufacturing partner focused on therapeutic peptides across development and commercial scales. What are the underlying business or industry changes driving this perspective?At CHF28.15, Is It Time To Put PolyPeptide Group AG (VTX:PPGN) On Your Watch List?
While PolyPeptide Group AG ( VTX:PPGN ) might not have the largest market cap around , it saw a significant share price...Market Cool On PolyPeptide Group AG's (VTX:PPGN) Revenues
PolyPeptide Group AG's ( VTX:PPGN ) price-to-sales (or "P/S") ratio of 2.4x might make it look like a buy right now...PolyPeptide Group (VTX:PPGN) Is Carrying A Fair Bit Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Earnings Update: Here's Why Analysts Just Lifted Their PolyPeptide Group AG (VTX:PPGN) Price Target To CHF31.29
SWX:PPGN 1 Year Share Price vs Fair Value Explore PolyPeptide Group's Fair Values from the Community and select yours...PolyPeptide Group AG's (VTX:PPGN) Shares Leap 28% Yet They're Still Not Telling The Full Story
Despite an already strong run, PolyPeptide Group AG ( VTX:PPGN ) shares have been powering on, with a gain of 28% in...Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...PolyPeptide Group AG (VTX:PPGN) Might Not Be As Mispriced As It Looks After Plunging 28%
To the annoyance of some shareholders, PolyPeptide Group AG ( VTX:PPGN ) shares are down a considerable 28% in the last...Why PolyPeptide Group AG (VTX:PPGN) Could Be Worth Watching
PolyPeptide Group AG ( VTX:PPGN ), is not the largest company out there, but it received a lot of attention from a...Many Still Looking Away From PolyPeptide Group AG (VTX:PPGN)
When close to half the companies operating in the Life Sciences industry in Switzerland have price-to-sales ratios (or...PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 19% Below Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, PolyPeptide Group fair value estimate is CHF25.02 PolyPeptide...PolyPeptide Group (VTX:PPGN) Is Making Moderate Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Sentiment Still Eluding PolyPeptide Group AG (VTX:PPGN)
You may think that with a price-to-sales (or "P/S") ratio of 3.7x PolyPeptide Group AG ( VTX:PPGN ) is a stock worth...Does PolyPeptide Group (VTX:PPGN) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Further Upside For PolyPeptide Group AG (VTX:PPGN) Shares Could Introduce Price Risks After 33% Bounce
PolyPeptide Group AG ( VTX:PPGN ) shareholders would be excited to see that the share price has had a great month...PolyPeptide Group AG's (VTX:PPGN) Intrinsic Value Is Potentially 99% Above Its Share Price
Key Insights The projected fair value for PolyPeptide Group is CHF39.76 based on 2 Stage Free Cash Flow to Equity...PolyPeptide Group AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
There's been a major selloff in PolyPeptide Group AG ( VTX:PPGN ) shares in the week since it released its yearly...Investors Shouldn't Be Too Comfortable With PolyPeptide Group's (VTX:PPGN) Robust Earnings
Despite posting some strong earnings, the market for PolyPeptide Group AG's ( VTX:PPGN ) stock hasn't moved much. Our...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | €3m | €864k | -€21m |
| Sep 30 2025 | n/a | n/a | -€28m |
| Jun 30 2025 | n/a | n/a | -€35m |
| Mar 31 2025 | n/a | n/a | -€27m |
| Dec 31 2024 | €3m | €842k | -€20m |
| Sep 30 2024 | n/a | n/a | -€24m |
| Jun 30 2024 | n/a | n/a | -€29m |
| Mar 31 2024 | n/a | n/a | -€40m |
| Dec 31 2023 | €2m | €604k | -€51m |
Compensation vs Market: Juan's total compensation ($USD3.62M) is above average for companies of similar size in the Swiss market ($USD1.56M).
Compensation vs Earnings: Juan's compensation has increased whilst the company is unprofitable.
CEO
Juan Gonzalez (53 yo)
Mr. Juan Jose Gonzalez serves as CEO at PolyPeptide Group AG since April 12, 2023. He had been Chief Executive Officer of Ambu A/S since May 15, 2019 until May 20, 2022 and supports the new CEO (Britt Meel...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 3.1yrs | €3.08m | 0.69% CHF 9.3m | |
| Interim CFO and Director of Investor Relations | less than a year | no data | no data | |
| Director of Corporate Finance | no data | no data | no data | |
| Director of Global Innovation & Technology | no data | no data | no data | |
| Head of Investor Relations & Corporate Communications | no data | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 4.7yrs | no data | no data | |
| Corporate Compliance Manager | no data | no data | no data | |
| Interim Director Global Sales & Marketing | no data | no data | no data | |
| Chief Human Resources Officer | 4yrs | no data | no data | |
| Head of Technical Department - Braine | no data | no data | no data | |
| Chief Information Security Officer & Global IT Services VC | no data | no data | no data | |
| Head of Internal Audit | no data | no data | no data |
Experienced Management: PPGN's management team is considered experienced (3.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Vice Chairman & Lead Independent Non-Executive Director | 5.3yrs | €237.36k | 0.084% CHF 1.1m | |
| Independent Non-Executive Chair of the Board of Directors | 5.3yrs | €356.62k | 0.13% CHF 1.7m | |
| Independent Non-Executive Director | 5.3yrs | €223.16k | 0.093% CHF 1.2m | |
| Non-Executive & Independent Director | 5.3yrs | €149.20k | 0.088% CHF 1.2m | |
| Non-Executive Director | 5.3yrs | no data | 0.0097% CHF 130.1k | |
| Independent Director | 1.1yrs | €165.65k | 0.0089% CHF 119.6k |
Experienced Board: PPGN's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/08 13:14 |
| End of Day Share Price | 2026/05/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PolyPeptide Group AG is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Pitman | Barclays |
| Estelle Bétrisey | Berenberg |
| Patrick Andrew Wood | BofA Global Research |